Fate Therapeutics to Unveil Phase 1 Data for FT836, FT819 and FT839 at ASCO, EULAR
FATE•Fate Therapeutics will present preliminary Phase 1 data for its FT836 MICA/B-targeted solid tumor CAR T-cell and safety/efficacy results for its FT819 anti-CD19 therapy at ASCO (May 30) and EULAR (June 4) meetings. Dual-CAR candidate FT839 targeting B and T cells in autoimmune diseases is scheduled for an oral EULAR session.
1. Upcoming ASCO Presentations
On May 30 in Chicago, Fate Therapeutics will showcase preliminary Phase 1 results for FT836, a MICA/B-targeted off-the-shelf CAR T-cell designed to overcome solid tumor escape mechanisms without conditioning chemotherapy. The poster session runs from 1:30–4:30 CT under the Developmental Therapeutics—Immunotherapy track.
2. EULAR Meeting Highlights
At the European Congress of Rheumatology on June 4 in London, FT819 will be featured in a poster tour (9:30 a.m. BST) presenting safety and efficacy data for off-the-shelf anti-CD19 CAR T-cell therapy with reduced conditioning enabling same-day discharge in SLE. Later that morning (8:15 a.m. BST), FT839’s dual-CAR candidate targeting B and T cells will receive an oral presentation in the new therapeutic targets session.
3. Strategic Pipeline Significance
These presentations underscore Fate’s iPSC-derived off-the-shelf platform, which offers uniform clonal master cell banks for scalable production, lower cost of goods, and rapid on-demand availability. Success in Phase 1 solid tumor and autoimmune studies could advance regulatory pathways and broaden patient access.
